The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of lenvatinib plus everolimus in advanced extra-pancreatic neuroendocrine tumors (epNETs): Updated results and real-world comparison.
 
Guglielmo Vetere
No Relationships to Disclose
 
Zhouxuan Li
No Relationships to Disclose
 
Wei Qiao
No Relationships to Disclose
 
Daniel Halperin
Consulting or Advisory Role - Amryt Pharma; Camurus; Chimeric Therapeutics; Crinetics Pharmaceuticals; Exelixis; Harbour BioMed; Harpoon therapeutics; Ipsen; Isotopen Technologien; Lantheus Medical Imaging; Novartis; Progenics; Radiomedix; Tersera
Research Funding - Advanced Accelerator Applications (Inst); Camurus (Inst); Genentech/Roche (Inst); Isotopen Technologien (Inst); RayzeBio (Inst); Tarveda Therapeutics (Inst); Thermo Fisher Scientific (Inst)
 
Venkateswar Surabhi
No Relationships to Disclose
 
Nir Stanietzky
No Relationships to Disclose
 
Mackenzie Phillips
No Relationships to Disclose
 
Divya Sakamuri
No Relationships to Disclose
 
Kaye Wilson
No Relationships to Disclose
 
Michael Leung
Honoraria - MJH Life Sciences
(OPTIONAL) Uncompensated Relationships - Hematology/Oncology Pharmacy Association
 
Makenna Smack
No Relationships to Disclose
 
James Yao
Consulting or Advisory Role - Acrotech Biopharma; Amgen; Crinetics Pharmaceuticals; Exelixis; Hutchison MediPharma; Ipsen
Research Funding - Advanced Accelerator Applications; Novartis
 
Arvind Dasari
Consulting or Advisory Role - HutcMed; Illumina/GRAIL; Personalis; SIRTIS; Takeda
Research Funding - Eisai (Inst); Guardant Health (Inst); Hutchison MediPharma (Inst); Merck (Inst); Natera (Inst); XENCOR (Inst)
Travel, Accommodations, Expenses - Hutchison MediPharma; Takeda